After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Recently, Yahoo Finance discussed the stock, revealing that Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, IRWD falls under the Healthcare sector while operating within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Ironwood Pharmaceuticals Inc is $2.35B. A total of 1.89 million shares were traded on the day, compared to an average of 2.89M shares.
Insider Activity
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, IRWD has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 20 BUYs and 28 SELLs from insiders. Insiders purchased 811,407 shares during that period but sold 326,952.
In the most recent transaction, MCCOURT Thomas A sold 177,164 shares of IRWD for 15.24 per share on Feb 12. After the transaction, the Chief Executive Officer now owns 832,774 company shares. In a previous transaction on Feb 12, John Minardo sold 47,380 shares at 15.24 per share. IRWD shares that Chief Legal Officer owns now total 224,796.
Among the insiders who sold shares, Shetzline Michael disposed of 38,618 shares on Feb 12 at a per-share price of $15.24. This resulted in the CMO,SVP,Head-Res&Drug holding 340,484 shares of IRWD after the transaction. In another insider transaction, Davis Andrew sold 9,846 shares at $15.24 per share on Feb 12. Company shares held by the SVP, Chief Business Officer now total 208,324.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for IRWD in the last 3 months, the mean price target is $20.67 with high estimates of $23.00 and low estimates of $18.00. In terms of 52-week highs and lows, IRWD has a high of $15.70 and a low of $8.07.
As of this writing, IRWD has an earnings estimate of $0.17 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $0.25 per share and a lower estimate of $0.11. The company reported an EPS of $0.09 in the last quarter, which was -43.80% lower than expectations of $0.16.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. IRWD’s latest balance sheet shows that the firm has $620.13M in Cash & Short Term Investments as of fiscal 2021. There were $475.80M in debt and $161.70M in liabilities at the time. Its Book Value Per Share was -$2.21, while its Total Shareholder’s Equity was $605.91M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IRWD is Buy with a score of 5.00.
